| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-06-27 | Daytwo (Israel) | $12 million | series A financing round | Seventure Partners (France), J&J (USA - NJ) historical investors | Series A financing round | |
| 2017-06-14 | Medixci (UK - Switzerland) | $300 million | financing round | Novartis (Switzerland) Verily, an Alphabet company (USA - CA) European Investment Fund (EIF) (EU) institutional LPs | Financing round | |
| 2017-06-09 | Idorsia (Switzerland) | IPO | Cardiovascular diseases - CNS diseases - Immune diseases - Rare diseases | IPO | ||
| 2017-06-06 | CTI BioPharma (USA - WA) | private placement | Cancer - Oncology | Private placement | ||
| 2017-05-30 | Glycomimetics (USA - Md) | $92.6 million | private placement | Cancer - Oncology | Private placement | |
| 2017-05-08 | Argen-X (Belgium - The Netherlands) | private placement | Private placement | |||
| 2017-05-05 | Amag Pharmaceuticals (USA - MA) | private placement | Private placement | |||
| 2017-05-05 | Achaogen (USA - CA) | up to $20.5 million | grant | Bill & Melinda Gates Foundation (USA) | Infectious diseases | Grant |
| 2017-05-04 | Vivet Therapeutics (France) | €37.5 million | series A financing round | Novartis Venture Fund (Switzerland) Columbus Venture Partners (Spain) Roche Venture Fund (Switzerland), HealthCap (Sweden) Kurma Partners (France) Ysios Capital (Spain) | Rare diseases - Metabolic diseases | Series A financing round |
| 2017-05-02 | Noxxon Pharma (Germany) | € 11 million | capital increase | Cancer - Oncology | Capital increase | |
| 2017-04-26 | RegenXBio (USA - MD) | $87.2 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2017-04-24 | Oryzon Genomics (Spain) | $300,000 | grant | Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY) | Neurodegenerative diseases | Grant |
| 2017-04-21 | Galapagos (Belgium) | €363.9 million | capital increase | Capital increase | ||
| 2017-04-17 | Arena Pharmaceuticals (USA - CA) | $79.4 million | private placement | Private placement | ||
| 2017-04-13 | Delmar Pharmaceuticals (USA - CA) | $ 9 million | private placement | Cancer - Oncology | Restructuring | |
| 2017-04-12 | Polyphor (Switzerland) | CHF 40 million (€ 37.43 million) | private placement | Varuma (Switzerland) Ingro Finanz (Switzerland) | Infectious diseases | Private placement |
| 2017-04-04 | Novosanis (Belgium) | € 200 000 | grant | Interreg CrossCare (Belgium) | Infectious diseases - Diagnostic | Grant |
| 2017-04-04 | Repositive (UK) | £2.5 million (€ 2.92 million) | series A financing round | Ananda Social Venture Fund (Germany) Force Over Mass Capital (UK) Amadeus Capital Partners (UK) Jonathan Milner | Technology - Services | Fundraising |
| 2017-03-31 | Osmia Pharmaceuticals (Sweden) | SEK 42 million (€ 4.4 million) | private placement | Cancer - Oncology - Veterinary medicine | Private placement | |
| 2017-03-31 | Aveo Pharmaceuticals (USA - MA) | $15.0 Million | private placement | Private placement |
